The webinar Reengineering CAR-T for solid tumors featuring presenters from Novartis and BMS (CAR-T therapies Kymriah and Breyanzi) is timely. Firstly, it allows investors to understand the out-of-the-box thinking by City of Hope scientists who are reengineering solid tumors for CAR-T therapies.
Secondly, it confirms the fact that success in bringing CAR-T to solid tumors will revolutionise the field. Thirdly, in the world of Pharma its a furious sprint to the finish line. One thing we know, everyone is watching. Looks like Imugene has jumped the start by running backwards from the Finish to the Start line where existing CAR-T therapies are safe and efficacious.
Analysts Reports (Imugene), page-71
-
- There are more pages in this discussion • 268 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 5.0¢ | 4.9¢ | $900.1K | 18.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 102 | 15456501 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 1713619 | 8 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |